360 related articles for article (PubMed ID: 30036855)
1. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
Setayeshgar S; Kingwell E; Zhu F; Zhang X; Zhang T; Marrie RA; Carruthers R; Tremlett H
Mult Scler Relat Disord; 2018 Oct; 25():57-60. PubMed ID: 30036855
[TBL] [Abstract][Full Text] [Related]
2. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
3. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis.
Dolladille C; Chrétien B; Peyro-Saint-Paul L; Alexandre J; Dejardin O; Fedrizzi S; Defer G
Neurotherapeutics; 2021 Jul; 18(3):1657-1664. PubMed ID: 34231126
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
[TBL] [Abstract][Full Text] [Related]
6. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
[TBL] [Abstract][Full Text] [Related]
7. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
[TBL] [Abstract][Full Text] [Related]
8. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
9. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
Setayeshgar S; Kingwell E; Zhu F; Zhang T; Carruthers R; Marrie RA; Evans C; Tremlett H
Mult Scler Relat Disord; 2019 Jan; 27():364-369. PubMed ID: 30476872
[TBL] [Abstract][Full Text] [Related]
10. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
Frahm N; Ellenberger D; Stahmann A; Fneish F; Lüftenegger D; Salmen HC; Schirduan K; Schaak TPA; Flachenecker P; Kleinschnitz C; Paul F; Krefting D; Zettl UK; Peters M; Warnke C
Ther Adv Neurol Disord; 2024; 17():17562864241239740. PubMed ID: 38560408
[TBL] [Abstract][Full Text] [Related]
11. Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study.
Kingwell E; Zhang T; Zhu F; Walld R; Carruthers R; Evans C; Marrie RA; Tremlett H
Expert Opin Drug Saf; 2021 Apr; 20(4):481-487. PubMed ID: 33342303
[TBL] [Abstract][Full Text] [Related]
12. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC
Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809
[TBL] [Abstract][Full Text] [Related]
13. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
[No Abstract] [Full Text] [Related]
14. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
15. Classifying PML risk with disease modifying therapies.
Berger JR
Mult Scler Relat Disord; 2017 Feb; 12():59-63. PubMed ID: 28283109
[TBL] [Abstract][Full Text] [Related]
16. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
Krysko KM; Graves JS; Rensel M; Weinstock-Guttman B; Rutatangwa A; Aaen G; Belman A; Benson L; Chitnis T; Gorman M; Goyal MS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rodriguez M; Rose J; Schreiner T; Tillema JM; Waltz M; Casper TC; Waubant E;
Ann Neurol; 2020 Jul; 88(1):42-55. PubMed ID: 32267005
[TBL] [Abstract][Full Text] [Related]
17. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
18. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Hartung DM; Bourdette DN; Ahmed SM; Whitham RH
Neurology; 2015 May; 84(21):2185-92. PubMed ID: 25911108
[TBL] [Abstract][Full Text] [Related]
19. Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.
Evans C; Marrie RA; Zhu F; Leung S; Lu X; Melesse DY; Kingwell E; Zhao Y; Tremlett H
Mult Scler Relat Disord; 2016 Jul; 8():78-85. PubMed ID: 27456879
[TBL] [Abstract][Full Text] [Related]
20. Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review.
Gasim M; Bernstein CN; Graff LA; Patten SB; El-Gabalawy R; Sareen J; Bolton JM; Marriott JJ; Fisk JD; Marrie RA;
Mult Scler Relat Disord; 2018 Nov; 26():124-156. PubMed ID: 30248593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
